Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod)
Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS)…
Read More...
Read More...
